OTCMKTS:ZRSEF DocMorris (ZRSEF) Stock Price, News & Analysis → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free ZRSEF Stock Alerts $95.77 0.00 (0.00%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$95.77▼$95.7750-Day Range$88.60▼$108.0552-Week Range$33.00▼$108.05VolumeN/AAverage Volume117 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartHeadlinesShort Interest Get DocMorris alerts: Email Address Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About DocMorris Stock (OTCMKTS:ZRSEF)DocMorris AG operates e-commerce pharmacies and a wholesale business for medical and pharmaceutical products in Switzerland and internationally. The company offers prescription and over-the-counter medicines, consumer health products, beauty and personal care products, nutritional supplements, painkillers, and first aid products. It also provides professional health care services. The company sells its products to online mail-order pharmacies, and private individuals under the PromoFarma by DocMorris, TeleClinic, and DocMorris brands. The company was formerly known as Zur Rose Group AG and changed its name to DocMorris AG in May 2023. DocMorris AG was founded in 1993 and is headquartered in Frauenfeld, Switzerland.Read More ZRSEF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ZRSEF Stock News HeadlinesApril 16, 2024 | markets.businessinsider.comDocMorris continues to grow in the first quarter of 2024 and creates digital access to the entire e-prescription marketApril 13, 2024 | americanbankingnews.comDocMorris AG (OTCMKTS:ZRSEF) Short Interest Up 21.7% in MarchApril 23, 2024 | The Bull Report (Ad)Healthcare Takes A Big Step Forward With The Help Of AIThe average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.March 23, 2024 | seekingalpha.comDocMorris AG (ZRSEF) Q4 2023 Earnings Call TranscriptMarch 21, 2024 | msn.comDocMorris AG reports FY results; initiates FY24 outlookMarch 6, 2024 | morningstar.comLeafly Holdings Inc LFLYJanuary 16, 2024 | morningstar.comDocMorris AG ZREJanuary 16, 2024 | markets.businessinsider.comDocMorris achieves significant revenue growth in the fourth quarter of 2023 and confirms inflection point by increasing active customer baseApril 23, 2024 | TradeSmith (Ad)The A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...January 9, 2024 | morningstar.comDocMorris AG DOCMJanuary 2, 2024 | wsj.comDocMorris N.V.December 17, 2023 | morningstar.comDocMorris AG ZRSEFDecember 8, 2023 | morningstar.comPineapple Inc PNPLNovember 11, 2023 | morningstar.comClicks Group Ltd ADR CLCGYAugust 17, 2023 | msn.comDocMorris AG GAAP EPS of CHF12.12, revenue of CHF462.9MMay 12, 2023 | msn.comUmbenennung: Online-Apotheke Zur Rose Group wird zu Doc MorrisMay 5, 2023 | markets.businessinsider.comAnnual General Meeting 2023: Zur Rose Group AG to be renamed DocMorris AG (stock exchange ticker symbol DOCM)May 4, 2023 | markets.businessinsider.comZur Rose Group has successfully completed the sale of its Swiss business to MigrosMarch 23, 2023 | news.yahoo.comZur Rose delays profitability break-even to 2024March 23, 2023 | marketwatch.comZur Rose Shares Slump After Pushing Break-Even Target to 2024February 8, 2023 | finanznachrichten.deZur Rose Group: Ist das der Beginn einer Trendwende?February 7, 2023 | msn.comZur Rose Group is upgraded by Deutsche Bank to a hold ratingFebruary 7, 2023 | investing.comCiti Upgrades Zur Rose Group AG to NeutralFebruary 3, 2023 | finanznachrichten.deZur Rose Group verabschiedet sich vom Schweizer Markt - Aktie springt nach obenFebruary 3, 2023 | markets.businessinsider.comZur Rose Group hands over successful Swiss business to Migros to focus on growth in GermanyJanuary 19, 2023 | finanznachrichten.deZur Rose Group: Aktie reagiert mit Kurssprung auf Erhöhung der ErgebnisprognoseJanuary 19, 2023 | msn.comOnline pharmacy Zur Rose improves 2022 core loss targetSee More Headlines Receive ZRSEF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DocMorris and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Retailers Sub-IndustryN/A Current SymbolOTCMKTS:ZRSEF CUSIPN/A CIKN/A Webwww.zurrosegroup.com Phone(152) 724-0020FaxN/AEmployees1,453Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Walter Oberhansli (Age 66)Founder & Chairman Comp: $478kMr. Walter Hess (Age 59)CEO & Member of Executive Board Comp: $1.51MMr. Marcel Ziwica (Age 49)CFO & Member of Executive Board Mr. David Maso (Age 53)Head of Europe & Member of Executive Board Mr. Madhu Nutakki (Age 53)CTO & Member of Executive Board Mr. Kaspar Niklaus (Age 56)COO & Member of Executive Board Dr. Daniel GrigatGroup Head of Investor Relations & SustainabilityMore ExecutivesKey CompetitorsAlibaba Health Information TechnologyOTC:ALBHFAllstar Health BrandsOTCMKTS:ALSTClicks GroupOTCMKTS:CLCGYFire & FlowerOTCMKTS:FFLWFHigh TideOTCMKTS:HITIFView All Competitors ZRSEF Stock Analysis - Frequently Asked Questions Should I buy or sell DocMorris stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DocMorris in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ZRSEF shares. View ZRSEF analyst ratings or view top-rated stocks. How have ZRSEF shares performed in 2024? DocMorris' stock was trading at $75.80 at the beginning of 2024. Since then, ZRSEF shares have increased by 26.3% and is now trading at $95.77. View the best growth stocks for 2024 here. Are investors shorting DocMorris? DocMorris saw a increase in short interest in March. As of March 31st, there was short interest totaling 255,400 shares, an increase of 21.7% from the March 15th total of 209,900 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is presently ∞ days. View DocMorris' Short Interest. How do I buy shares of DocMorris? Shares of ZRSEF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:ZRSEF) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishingtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DocMorris AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
